Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019 ; interim data suggests reduction in severe anemia and thrombocytopenia; encouraging results led to the plan
